表皮生长因子受体-酪氨酸激酶抑制剂联合抗血管生成药物治疗非小细胞肺癌的研究进展  

Research advances in EGFR-TKI combined with anti-angiogenic therapy for NSCLC

作　　者：叶丽 李亚颖 郑晨杰 叶恋娟 Ye Li;Li Yaying;Zheng Chenjie;Ye Lianjuan(Department of Hematology-Oncology,Longquan People's Hospital,Longquan,Zhejiang 323700,China)

机构地区：[1]浙江省龙泉市人民医院血液肿瘤科,浙江龙泉323700

出　　处：《中国药物与临床》2025年第7期470-476,共7页Chinese Remedies & Clinics

摘　　要：表皮生长因子受体(EGFR)突变阳性非小细胞肺癌(NSCLC)患者的治疗策略近年来逐渐向一线EGFR酪氨酸激酶抑制剂(TKI)与血管生成抑制剂联合应用转变。诸多一线研究表明联合治疗能够提高患者的无进展生存期和总体生存期。基于此,本研究回顾了第一、二、三代EGFR-TKI联合抗血管生成药物治疗的相关文献,总结了EGFR-TKI与血管生成抑制剂的联合治疗模式(A+T治疗模式)的增益机制、获益程度、安全性以及最佳的目标人群。未来的研究应继续聚焦于如何将心理支持与治疗方案结合,从而促进EGFR突变阳性NSCLC患者的整体治疗效果。The treatment strategy for epidermal growth factor receptor(EGFR)mutation-positive non-small cell lung cancer(NSCLC)has progressively shifted toward first-line combination therapy using EGFR tyrosine kinase inhibitors(TKIs)with angiogenesis inhibitors in recent years.Multiple first-line studies have demonstrated that this combination therapy can improve both progression-free survival and overall survival in patients.Based on these findings,this study reviews relevant literature on the combination of first-,second-,and third-generation EGFR-TKIs with anti-angiogenic drugs,summarizing the synergistic mechanisms,clinical benefits,safety profile,and optimal target population of the"A+T"(anti-angiogenic+TKI)treatment model.Future research should continue to explore how psychological support can be integrated into treatment regimens to enhance the overall therapeutic outcomes for patients with EGFR mutation-positive NSCLC.

关 键 词：癌 非小细胞肺 心理配合 酪氨酸激酶抑制剂 抗血管生成药物 厄洛替尼 

分 类 号：R734.2[医药卫生—肿瘤]